中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study

文献类型：期刊论文

作者Wang, Wenxian7,8; Gu, Xiaodong7,8; Si, Jinfei7,8; Pu, Xingxiang6; Wang, Liping5; Chen, Huafei4; Xu, Chunwei3; Zhang, Xiaoyan2; Yuan, Hongling2; Lou, Guangyuan7,8
刊名GENES CHROMOSOMES & CANCER
出版日期2022-04-23
关键词BRAF mutation immune checkpoint inhibitors non-small cell lung cancer PD-L1 targeted therapy
ISSN号1045-2257
DOI10.1002/gcc.23043
通讯作者Zhang, Gu(zjch1971@163.com) ; Song, Zhengbo(zheng_bo_song@163.com)
英文摘要The incidence of primary and acquired BRAF mutations is low in non-small cell lung cancer (NSCLC), with limited demographic and treatment outcome data available for this patient population. We evaluated lung cancer samples with programmed cell death ligand 1 (PD-L1) information extracted from 12 051 cases (cohort A) of lung cancer from OncoPanscan (TM)-based sequencing of tissue (Genetron Health) and conducted retrospective multicenter data analysis using the database of Zhejiang Cancer Hospital and four other centers (cohort B, including 73 primary BRAF mutation and 14 acquired BRAF mutation cases) to compare treatment outcomes of patient groups with primary and acquired BRAF mutations. In cohort A, after propensity score analysis, 165 samples of NSCLC with BRAF mutations were screened along with 165 paired non-BRAF mutation samples. We observed no significant differences in the proportion of samples with >= 1% PD-L1 between BRAF and non-BRAF mutant groups. The median progression-free survival (mPFS) period in 13 patients with primary BRAF mutations receiving BRAF tyrosine kinase inhibitors (BRAF-TKIs) was 7.0 months. The group with primary BRAF mutations receiving immune checkpoint inhibitor (ICI) combination chemotherapy had better PFS than those administered ICI monotherapy (14.77 months vs. 5.0 months, p = 0.025) and similar results were obtained for OS (unreached vs. 20.3 months, p = 0.013). For acquired BRAF mutations, mPFS of BRAF-TKI, ICI-based, and chemotherapy-based regimens were 3.8, 1.5, and 1.9 months, respectively. Therefore, for patients with the primary BRAF V600E mutation, targeted therapy or immunochemotherapy could serve as effective treatment choices, while for those with acquired BRAF V600E, targeted drug therapy may remain the preferred solution in China.
WOS关键词DABRAFENIB PLUS TRAMETINIB ; DURABLE CLINICAL-RESPONSE ; OPEN-LABEL ; MUTATIONS ; NSCLC ; OSIMERTINIB ; CRIZOTINIB ; DOCETAXEL ; MECHANISM ; SURVIVAL
资助项目Huilan Public-Hanson Pharmaceutical Lung Cancer Precision Medical Research Special Fund Project Foundation ; Xisike-Hanson Cancer Research Foundation ; Zhejiang Chinese Medical Science and Technology Foundation ; Cancer Research Foundation[HS2020-5] ; Cancer Research Foundation[HS2019-20] ; Cancer Research Foundation[2021ZQ013]
WOS研究方向Oncology ; Genetics & Heredity
语种英语
WOS记录号WOS:000785909100001
出版者WILEY
资助机构Huilan Public-Hanson Pharmaceutical Lung Cancer Precision Medical Research Special Fund Project Foundation ; Xisike-Hanson Cancer Research Foundation ; Zhejiang Chinese Medical Science and Technology Foundation ; Cancer Research Foundation
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/128589]  
专题中国科学院合肥物质科学研究院
通讯作者Zhang, Gu; Song, Zhengbo
作者单位1.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Pathol, Hangzhou, Peoples R China
2.Genetron Hlth Beijing Technol Co Ltd, Dept Translat Med, Beijing, Peoples R China
3.Nanjing Univ, Affiliated Jinling Hosp, Med Sch, Dept Resp Med, Nanjing, Jiangsu, Peoples R China
4.Zhejiang Rongjun Hosp, Dept Thorac Dis Ctr, Jiaxing, Zhejiang, Peoples R China
5.Baotou Canc Hosp, Dept Oncol, Baotou, Inner Mongolia, Peoples R China
6.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Med Oncol, Changsha, Peoples R China
7.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China
8.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Wenxian,Gu, Xiaodong,Si, Jinfei,et al. Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study[J]. GENES CHROMOSOMES & CANCER,2022.
APA Wang, Wenxian.,Gu, Xiaodong.,Si, Jinfei.,Pu, Xingxiang.,Wang, Liping.,...&Song, Zhengbo.(2022).Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study.GENES CHROMOSOMES & CANCER.
MLA Wang, Wenxian,et al."Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study".GENES CHROMOSOMES & CANCER (2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。